SCHEMBL6674733

SCHEMBL6674733

O=S(=O)(Cl)c1cc(Br)c(F)c(F)c1F

nearest known ligand 0.32

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.32
CA1 P00915 6/20 0.31
CA2 P00918 6/20 0.31
CA12 O43570 2/20 0.31
CA7 P43166 2/20 0.31
CA13 Q8N1Q1 2/20 0.31
CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30291227 0.78 TRPV4 (0.36) TRPV4CA1CA2
SCHEMBL6736791 0.78 TRPV4 (0.36) TRPV4CA1CA2
SCHEMBL29671274 0.77 CA12 (0.38) TRPV4CA1CA2CA12CA7
SCHEMBL1535900 0.77 CA12 (0.38) TRPV4CA1CA2CA12CA7
SCHEMBL14120615 0.75 EPAS1 (0.38) CA1CA2CA9
SCHEMBL1349380 0.74 CA1 (0.35) TRPV4CA1CA2CA12CA7
SCHEMBL2446550 0.74 TTR (0.46) CA1CA2CA12CA7CA13
SCHEMBL6894752 0.72 TRPV4 (0.32) TRPV4CA1CA2CA12CA7
SCHEMBL25379068 0.72 CA1 (0.38) TRPV4CA1CA2CA12CA7
SCHEMBL15575105 0.71 MAPK1 (0.34) CA1CA2CA12CA7CA13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1005453-B1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE LOWERING AGENTS TULARIK INC (US) 2004-10-27 EP disclosed
EP-1090014-B1 ARYLSULFONANILIDE PHOSPHATES TULARIK INC (US) 2003-09-03 EP disclosed
US-6417176-B2 ANTICANCER AGENTS, PSORIASIS, RESTENOSIS, ATHEROSCLEROSIS TULARIK, INC. 2002-07-09 US disclosed
US-6388131-B2 Benzenesulfonamide compounds, which encompasses the compound batabulin (2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene) TULARIK, INC. 2002-05-14 US disclosed
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US disclosed
US-6284923-B1 BENZENESULFONIMIDES FOR TREATMENT OF CANCER AND ANTICHOLESTEROL AGENTS TULARIK INC 2001-09-04 US disclosed
US-20010018430-A1 Arylsulfonanilide phosphates TULARIK, INC. 2001-08-30 US disclosed
EP-1090014-A1 ARYLSULFONANILIDE PHOSPHATES Tularik Inc. (US) 2001-04-11 EP disclosed
US-6211167-B1 ANTICHOLESTEROL, ANTIPROLIFERATIVE AND ANTILIPEMIC AGENTS; CANCER, PSORIASIS, ATHEROSCLEROSIS, INFECTION AND VASCULAR RESTENOSIS TREATMENT TULARIK INC. 2001-04-03 US disclosed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP disclosed
WO-1999067258-A1 ARYLSULFONANILIDE PHOSPHATES TULARIK INC. (US) 1999-12-29 WO disclosed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 TRPV4 1342/4885CA1 4659/4885CA2 3895/4885
US-20010018430-A1 Arylsulfonanilide phosphates PIK3CA, INPP5D, INPPL1 TRPV4 828/4885CA1 4626/4885CA2 3068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.